The present study revealed, for the first time, the anti-proliferative, anti-migration, EMT inhibition and apoptotic activities of azilsartan, which is an ARB, against MCF-7 and MDA-MB-231 breast cancer cell lines through modulating the NF-kB/IL-6/JAK2/STAT3/MMP9, TWIST/SNAIL/SLUG and bax/bcl2 mediated caspase-dependent signaling pathways. Here, JAK2 is linked to breast cancer.